PolyPid (PYPD) Cash & Equivalents (2019 - 2026)

PolyPid has reported Cash & Equivalents for 8 years, with the latest figure at $8.9 million in Q1 2026.

• Quarterly Cash & Equivalents rose 291.2% year-over-year to $8.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.9 million (up 291.2% YoY) and the FY2025 annual result came in at $6.4 million, down 59.07% from the prior year.
• Cash & Equivalents climbed to $8.9 million in Q1 2026 per PYPD's latest filing, from $6.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $17.4 million in Q2 2025 and troughed at $1.4 million in Q3 2023.
• A 5-year average of $8.1 million and a median of $6.4 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents tumbled 91.6% in 2023, then soared 467.23% in 2025.
• Over 5 years, Cash & Equivalents stood at $8.6 million in 2022, then sank by 37.92% to $5.3 million in 2023, then soared by 194.61% to $15.6 million in 2024, then tumbled by 59.07% to $6.4 million in 2025, then soared by 38.83% to $8.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $8.9 million, $6.4 million, and $9.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.